SCHEMBL51305

SCHEMBL51305

O=c1c2ccccc2sc2cccc(Oc3ccccc3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
MAPT P10636 4/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
MAOA P21397 3/20 0.44
MAOB P27338 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
GAA P10253 2/20 0.41
POLB P06746 2/20 0.41
GPR3 P46089 1/20 0.39
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29731425 1.00 NPC1 (0.51) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL8091142 0.90 MAPT (0.56) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL28934062 0.87 GPR3 (0.45) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL3416670 0.82 NPC1 (0.49) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL9127401 0.81 KDM4E (0.49) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL2789108 0.81 NPC1 (0.70) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL30925001 0.81 NPC1 (0.70) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL9128843 0.80 MAPT (0.55) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL7098554 0.80 MAPT (0.50) NPC1RAB9AMAPTCYP1A2CYP3A4
SCHEMBL6688700 0.78 NPC1 (0.51) NPC1RAB9AMAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 US claimed
CN-107652222-B Oxime ester photoinitiators 巴斯夫欧洲公司 2021-09-10 CN claimed
US-10919909-B2 Photoinitiated reactions LINTFIELD LIMITED (GB) 2021-02-16 US claimed
US-20190211031-A1 PHOTOINITIATED REACTIONS LINTFIELD LIMITED (GB) 2019-07-11 US claimed
US-20190046463-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME ICURE PHARMACEUTICAL INC. (KR) 2019-02-14 US claimed
EP-3415141-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME Icure Pharmaceutical Inc. (KR) 2018-12-19 EP claimed
US-12637600-B2 Photocurable composition, cured product of same, photofusible resin composition and adhesive set RESONAC CORPORATION (JP) 2026-05-26 US disclosed
US-20260132243-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTOMELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RESONAC CORP (JP) 2026-05-14 US disclosed
EP-4555025-B1 PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS, FURTHER ACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS IGM GROUP B V (NL) 2026-05-13 EP disclosed
EP-3902878-B1 PHOTOINITIATORS IGM RESINS ITALIA SRL (IT) 2026-05-06 EP disclosed
EP-4410859-B1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTO-MELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RESONAC CORP (JP) 2026-04-29 EP disclosed
EP-4534614-B1 PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS, FURTHER ACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS IGM GROUP B V (NL) 2026-04-15 EP disclosed
EP-4722303-A1 PHOTOINITIATOR PACKAGE COMPRISING SPECIALISED BISACYLPHOSPHINE OXIDE PHOTOINITIATORS, FURTHER ACYLPHOSPHINE OXIDE PHOTOINITIATORS AND OPTICAL BRIGHTENER SENSITIZERS IGM Group B.V. (NL) 2026-04-08 EP disclosed
WO-2001058971-A2 PROCESS FOR THE PRODUCTION OF STRONGLY ADHERENT SURFACE-COATINGS BY PLASMA-ACTIVATED GRAFTING CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-08-16 WO disclosed
US-20010012596-A1 For resist applications; thermostability, storage stability CIBA SPECIALTY CHEMICALS CORP. 2001-08-09 US disclosed
WO-2001042313-A1 ADDITIVE COMPOSITION FOR INCREASING THE STORAGE STABILITY OF ETHYLENICALLY UNSATURATED RESINS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-06-14 WO disclosed
EP-1095313-A1 PHOTOPOLYMERIZABLE THERMOSETTING RESIN COMPOSITIONS Ciba SC Holding AG (CH) 2001-05-02 EP disclosed
WO-2000052530-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-09-08 WO disclosed
WO-2000024527-A1 METHOD FOR PRODUCING ADHESIVE SURFACE COATINGS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-05-04 WO disclosed
WO-2000000869-A1 PHOTOPOLYMERIZABLE THERMOSETTING RESIN COMPOSITIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637600-B2 Photocurable composition, cured product of same, photofusible resin composition and adhesive set ESD, CDH1, ASH2L NPC1 4105/4885RAB9A 4022/4885MAPT 2260/4885
US-10919909-B2 Photoinitiated reactions KMO, DECR1, PPOX NPC1 2000/4885RAB9A 3269/4885MAPT 1604/4885
US-20190211031-A1 PHOTOINITIATED REACTIONS DOHH, PAH, DBH NPC1 2594/4885RAB9A 4138/4885MAPT 1061/4885
US-20260132243-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTOMELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RER1, OXTR, MAP1LC3A NPC1 4792/4885RAB9A 3549/4885MAPT 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.